CHU Gabriel-Montpied
- Address
- lock Available on a paid plan
Nephrology and Kidney Health
At CHU Gabriel-Montpied the nephrology unit focuses on advancing treatments for chronic kidney conditions, transplant outcomes, and immune‑mediated renal diseases.
- Chronic Kidney Disease
- IgA nephropathy
- Lupus Nephritis
- Kidney Transplantation
- BKV infection
- Glycogen storage disease type II
With 62 active trials and a team of 65 investigators, the department evaluates novel therapies, preventive strategies, and diagnostic tools to preserve renal function.
Oncology Clinical Research
The site conducts studies targeting a range of solid tumours, aiming to improve survival and reduce recurrence through innovative drug combinations and immunotherapies.
- Non‑small cell lung cancer
- Gastric and gastro‑esophageal junction cancer with FGFR2b overexpression
- Bladder carcinoma in situ (BCG‑unresponsive)
- Head and neck cancer
- Penile carcinoma
- Pleural mesothelioma
These 62 trials include investigations of targeted agents, checkpoint inhibitors, and antibody‑drug conjugates, reflecting a strong commitment to personalized oncology.
Neurology & Neuro‑degeneration
Research in the neurological field explores disease‑modifying approaches for multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis, seeking to slow progression and improve quality of life.
- Relapsing multiple sclerosis
- Primary progressive multiple sclerosis
- Early Parkinson’s disease
- Amyotrophic Lateral Sclerosis
- Diffuse intrinsic pontine glioma
- Chronic inflammatory demyelinating polyneuropathy
The collaborative effort leverages advanced imaging and biomarkers to assess therapeutic impact across 62 trials.
Cardiovascular and Metabolic Studies
Investigations address atherosclerotic disease, heart failure, and obesity‑related cardiovascular risk, testing novel lipid‑lowering agents and heart‑failure management strategies.
- Atherosclerotic cardiovascular disease
- Heart failure with recovered ejection fraction
- Inclisiran for cardiovascular events
- Obesity and weight management
- Venous thromboembolism
- Pulmonary arterial hypertension
The department’s trials aim to reduce major adverse cardiac events and improve long‑term vascular health.
Respiratory and Pulmonary Research
Clinical work in the respiratory area evaluates treatments for lung cancer, pulmonary hypertension, and severe pneumonia, focusing on survival and functional outcomes.
- Stage III unresectable NSCLC
- Inoperable chronic thromboembolic pulmonary hypertension
- Hospital‑acquired pneumonia
- Acute respiratory failure in immunocompromised patients
- Pulmonary arterial hypertension
- NSCLC with KRAS G12C mutation
Trials incorporate immunotherapy, targeted therapy, and novel anticoagulation regimens to address unmet needs.
Immunology and Autoimmune Disorders
The centre evaluates biologic agents for immune‑mediated diseases such as lupus, IgA nephropathy, and myasthenia gravis, aiming to modulate pathogenic pathways.
- Systemic lupus erythematosus
- Lupus nephritis
- IgA nephropathy
- Generalized myasthenia gravis
- VEXAS syndrome
- Bacterial vaginosis
These studies test complement inhibitors, BTK inhibitors, and immunoglobulin therapies to achieve disease control.
Infectious Disease and Transplant Research
Focused on preventing viral reactivation and bacterial complications, the site’s trials assess prophylactic immunoglobulins and antiviral strategies in transplant recipients.
- BKV infection in kidney transplant
- EBV primary infection prevention
- Hospital‑acquired pneumonia
- Bacterial vaginosis
- Virus diseases
- Bacterial infections and mycoses
By integrating virology and immunology, the program supports safer transplantation and reduced infection‑related morbidity.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 21 therapeutic areas and 15 of 174 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 160 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 35 by active trials.
lock +34 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG7trials
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Gabriel-Montpied
lock Showing 1 of 94 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 174 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 7 | Unknown | 2018-05-02 | 2026-02-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.